About $20 million which should last 3-4 years (last report expense $3.5m). Shareprice seems to have a solid bottom at 19c. The next year should be key as to how cx bladder is accepted in the new markets. Not much on sales yet - NZ & Aus starting now and states to come in late 2012. Quality partners should help eg Healthscope, Penn state uni.
Strong $NZ so good time to be investing o seas. Can't see much sign of broad institutional support yet - no AMP or govtsuper or ACC on the register last ann report.